Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Eptifibatide (Integrilin) vs Etelcalcetide (Parsabiv)
An educational, source-based comparison of Eptifibatide (Integrilin) and Etelcalcetide (Parsabiv) — how each peptide works, what it's researched for, and what to know before going deeper.
GP IIb/IIIa inhibitor cyclic peptide for ACS and PCI.
Cyclic heptapeptide derived from rattlesnake venom that reversibly blocks platelet glycoprotein IIb/IIIa receptors, preventing fibrinogen binding and platelet aggregation.
- Acute coronary syndromes
- PCI
- • FDA-approved.
- • Bleeding risk; renal adjustment required.
Calcimimetic peptide for secondary hyperparathyroidism on hemodialysis.
Synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells, increasing its sensitivity to extracellular calcium and lowering PTH secretion.
- Secondary hyperparathyroidism in adults on chronic hemodialysis
- • FDA-approved.
- • Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Eptifibatide (Integrilin) | PURSUIT trial | NEJM | 1998 | Reduced death/MI in non-ST-elevation ACS. |
| Etelcalcetide (Parsabiv) | Etelcalcetide vs cinacalcet | JAMA | 2017 | Non-inferior PTH reduction with IV administration. |
Side-effect & safety grid
- FDA-approved.
- Bleeding risk; renal adjustment required.
- FDA-approved.
- Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Eptifibatide (Integrilin) vs Etelcalcetide (Parsabiv) — Key differences
- Class: Eptifibatide (Integrilin) is classified as Antiplatelet · Cardiology, while Etelcalcetide (Parsabiv) is Calcium-Sensing Receptor Agonist · Endocrine.
- Primary research focus: Eptifibatide (Integrilin) — acute coronary syndromes; Etelcalcetide (Parsabiv) — secondary hyperparathyroidism in adults on chronic hemodialysis.
- Tag: FDA-Approved · Cardiology vs FDA-Approved · Endocrine.